TrialJapanese journal of clinical oncology2021

Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.

K Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.